澳大利亞CSL Biotherapies
CSL Biotherapies的美國總部位于賓夕法尼亞州的普魯士王(King of Prussia)市;其位于澳大利亞墨爾本市的母公司CSL Limited擁有世界上最大的流感疫苗生產基地之一,可向全球市場供貨。CSL Biotherapies向全球營銷流感疫苗產品,它與子公司CSL Behring共用美國總部的辦公場所。在CSL Biotherapies公司,我們的使命是生產疫苗,我們的激情在于呵護生命。CSL集團還包括CSL Research & Development、CSL Bioplasma以及CSL Behring等部門或子公司,它擁有8600多名員工,在全球27個國家開展業務。
CSL集團包括CSL Bioplasma、CSL Biotherapies以及CSL Behring并購的ZLB Plasma公司。CSL的主要生產基地位于澳大利亞、德國、瑞士與美國境內,它在27個國家共雇用了8600多名員工。
CSL Biotherapies manufactures, sells and distributes influenza vaccine worldwide.
CSL Biotherapies draws on the combined heritage and expertise of the CSL Group in the United States, Europe, Asia, Australia and New Zealand to provide safe and reliable products to our customers.
In Australia, CSL Biotherapies markets a comprehensive range of Vaccines and Antivenoms as well as a range of pharmaceutical products supplied by other manufacturers.
CSL Biotherapies understands the influenza vaccine business and customers’ needs for reliable and safe flu vaccine supplies. Our long-established parent, CSL Limited, has been producing flu vaccine without disruption for nearly four decades. Based in Melbourne, Australia, CSL provides flu vaccine to Australia, New Zealand, and more than 16 countries in Europe, South America and Asia.
Beginning with the 2007-2008 season, CSL Biotherapies has been contributing to meeting the growing demand in the United States for reliable supplies of flu vaccine each year. CSL Biotherapies is ideally positioned to become a reliable resource for healthcare professionals who actively embrace the United States government’s flu immunization recommendations.
Millions of people outside the United States already rely on CSL for their flu vaccine. CSL Biotherapies offers several competitive advantages to health care professionals in search of timely delivery of high-quality flu vaccines.